Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Qingxia F"'
Autor:
Deyi Zhao, Miran Tang, Zhexiao Ma, Panjie Hu, Qingxia Fu, Zhuocheng Yao, Cui Zhou, Tieli Zhou, Jianming Cao
Publikováno v:
Virulence, Vol 15, Iss 1 (2024)
The hypervirulent Klebsiella pneumoniae (hvKp) with K1 and K2 capsular types causes liver abscess, pneumonia, sepsis, and invasive infections with high lethality. The presence of capsular polysaccharide (CPS) resists phagocytic engulfment and contrib
Externí odkaz:
https://doaj.org/article/2823d72ae82a47a99e2c891b45fcaad0
Autor:
Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Yiwei Dou, Qian Tan, Di Wu, Jun Guo
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. Metho
Externí odkaz:
https://doaj.org/article/83c21142fb064ae8ae697bb5f09ec8bc
Autor:
Yu Meng, Congcong Wang, Lijie Song, Zewen Su, Yaojun Jiang, Yanbang Lian, Gongxun Bai, Qingxia Fan
Publikováno v:
Materials & Design, Vol 233, Iss , Pp 112201- (2023)
The use of functional nanomaterials to realize tumor therapeutic therapy has received considerable attention. However, a single type of nanomaterial usually can only achieve one specific function, and may cause biosafety problems due to poor metaboli
Externí odkaz:
https://doaj.org/article/01fce6a5136c4cc6978a3ac5d4f4e2b9
Publikováno v:
Cancer Biology & Therapy, Vol 23, Iss 1, Pp 1-8 (2022)
Defects in tRNA expressions and modifications had been linked to various types of tumorigenesis and progression in recent studies, including colorectal cancer. In the present study, we evaluated transcript levels of mitochondrial tyrosyl-tRNA synthet
Externí odkaz:
https://doaj.org/article/6783e5c655204b4da0e17a13e313e486
Autor:
Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Yuxian Bai, Wei Li, Yiping Zhang, Guanghai Dai, Dong Ma, Jingdong Zhang, Chunmei Bai, Yunchao Huang, Wangjun Liao, Lin Wu, Xi Chen, Yan Yang, Junye Wang, Shoujian Ji, Hui Zhou, Yan Wang, Zhuo Ma, Yanqi Wang, Bo Peng, Jiya Sun, Christoph Mancao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal
Externí odkaz:
https://doaj.org/article/ca3209d28c2d4a36b8c9ded73e1588cf
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0281402 (2023)
BackgroundSunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinic
Externí odkaz:
https://doaj.org/article/776aa9cac81d488e81e0fce4dc9621ee
Autor:
Zhi Peng, Tianshu Liu, Jia Wei, Airong Wang, Yifu He, Liuzhong Yang, Xizhi Zhang, Nanfeng Fan, Suxia Luo, Zhen Li, Kangsheng Gu, Jianwei Lu, Jianming Xu, Qingxia Fan, Ruihua Xu, Liangming Zhang, Enxiao Li, Yuping Sun, Guohua Yu, Chunmei Bai, Yong Liu, Jiangzheng Zeng, Jieer Ying, Xinjun Liang, Nong Xu, Chao Gao, Yongqian Shu, Dong Ma, Guanghai Dai, Shengmian Li, Ting Deng, Yuehong Cui, Jianmin Fang, Yi Ba, Lin Shen
Publikováno v:
Cancer Communications, Vol 41, Iss 11, Pp 1173-1182 (2021)
Abstract Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemist
Externí odkaz:
https://doaj.org/article/84d42b69d5e24a3c9b4936b33833bf96
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Objective Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC). The objective of this study was
Externí odkaz:
https://doaj.org/article/59b2d26346254d8aa66b691292ca36d0
Autor:
Rongrui Liu, Lianke Liu, Chuanhua Zhao, Yuxian Bai, Yulong Zheng, Shu Zhang, Ning Li, Jianwei Yang, Qingxia Fan, Xiuwen Wang, Shan Zeng, Yingjun Zhang, Weihong Zhang, Yulei Zhuang, Ning Kang, Yingzhi Jiang, Hongmei Sun, Jianming Xu
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squ
Externí odkaz:
https://doaj.org/article/c296492a15704d349fdc15b8b90df437
Autor:
Yiqun Li, Yanfeng Wang, Ning Li, Xinjun Liang, Shu Zhang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Binghe Xu, Jing Huang, Ningning Wang
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 8, Pp 988-990 (2022)
Externí odkaz:
https://doaj.org/article/ef9952c7921c4dc8befe482fde05f0d6